Drug Trial Radar · NCT00772603
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
Last checked: Nov 19, 2026Latest source record: Feb 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Nov 2008
Primary completion
Apr 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the safety and efficacy of Oxcarbazepine XR as adjunctive treatment for adults with partial onset seizures
Conditions
- Epilepsies, Partial
Interventions
PlaceboDrug
Non-active tablet identical to study drug tablets
2400mg SPN-804Drug
tablets containing 600mg OXC XR, identical to non-active tablets
1200mg SPN-804Drug
two active tablets and two non-active tablets, all identical
Primary outcomes
What the sponsor says the trial is designed to measure.
- PCH(T), ITTTime frame: Change at 16 weeks (4wks Titration + 12 wks Maintenance) compared to Baseline
Locations
71 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Northport, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Riverside, California
Site not named
West Los Angeles, California
Site not named
Aurora, Colorado
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Sarasota, Florida
Site not named
Atlanta, Georgia
Site not named
Springfield, Illinois
Site not named
Lexington, Kentucky
Site not named
Bethesda, Maryland
Site not named
Missoula, Montana
Site not named
Camden, New Jersey
Site not named
New York, New York
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Baytown, Texas
Site not named
Temple, Texas
Site not named
Blagoevgrad, Bulgaria
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Rousse, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Edmonton, Alberta, Canada
Site not named
Greenfield Park, Quebec, Canada
Site not named
Dubrovnik, Croatia
Site not named
Rijeka, Croatia
Site not named
Zadar, Croatia
Site not named
Zagreb, Croatia
Site not named
Aguascalientes, Aguascalientes, Mexico
Site not named
Chihuahua City, Chihuahua, Mexico
Site not named
Ciudad Juárez, Chihuahua, Mexico
Site not named
Durango, Durango, Mexico
Site not named
Guadalajara, Jalisco, Mexico
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.